Biotech · Private company · Blacksburg, VA, US
BioTherapeutics Inc.
Track this companyFree. Adds BioTherapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials1
- Abscisic Acid Effects on Glucose Homeostasis and Insulin SensitivityPHASE2 · COMPLETED · started Mar 8, 2021ClinicalTrials.gov NCT04722354 · fetched Nov 12, 2026
NIH awards10
- Immunometabolic Therapeutics for Alzheimer's DiseaseFiscal year 2026 · $500KNIH RePORTER 1R43AG102078-01 · fetched Nov 12, 2026
- Novel Immunoregulatory Therapeutics for Bacterial GastritisFiscal year 2026 · $314.4KNIH RePORTER 1R43AI197314-01 · fetched Nov 12, 2026
- Immunometabolic Therapeutics for Multiple SclerosisFiscal year 2026 · $314.4KNIH RePORTER 1R43AI197370-01 · fetched Nov 12, 2026
- A First-in-class Topical Immunoregulatory Therapeutic for PsoriasisFiscal year 2026 · $191.3KNIH RePORTER 5R44AR083730-03 · fetched Nov 12, 2026
- Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBDFiscal year 2025 · $314.4KNIH RePORTER 1R43AI188776-01A1 · fetched Nov 12, 2026
- Next-Gen Oral Therapeutics for Type 2 DiabetesFiscal year 2025 · $359.6KNIH RePORTER 1R43DK142279-01A1 · fetched Nov 12, 2026
- The Next Wave of Asthma TherapeuticsFiscal year 2025 · $347.6KNIH RePORTER 1R43HL177843-01 · fetched Nov 12, 2026
- Novel Therapeutic for SLEFiscal year 2025 · $314.4KNIH RePORTER 1R44AI192080-01A1 · fetched Nov 12, 2026
- A First-in-class Topical Immunoregulatory Therapeutic for PsoriasisFiscal year 2025 · $1.9MNIH RePORTER 2R44AR083730-02A1 · fetched Nov 12, 2026
- Comparative Efficacy of Therapeutics for Clostridioides difficile InfectionFiscal year 2024 · $300KNIH RePORTER 1R43AI184008-01A1 · fetched Nov 12, 2026